Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION: When comprehensively reviewing the available literature, no clear and significant associations between liraglutide and pancreatitis and/or pancreas cancer seem evident. However, a recently published analysis suggests a trend toward a slightly elevated risk of pancreatitis with GLP-1 receptor agonists (including liraglutide), which may become statistical significant as more data become available. Well-established side effects are of gastrointestinal origin, typical mild-to-moderate and of transient character. The risk of hypoglycemia associated with liraglutide treatment is low.
|
Authors | Thor Chalmer, Thomas P Almdal, Tina Vilsbøll, Filip K Knop |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 14
Issue 1
Pg. 171-80
(Jan 2015)
ISSN: 1744-764X [Electronic] England |
PMID | 25363438
(Publication Type: Journal Article, Review)
|
Chemical References |
- GLP1R protein, human
- Glucagon-Like Peptide-1 Receptor
- Hypoglycemic Agents
- Receptors, Glucagon
- Liraglutide
- Glucagon-Like Peptide 1
|
Topics |
- Diabetes Mellitus, Type 2
(drug therapy)
- Glucagon-Like Peptide 1
(adverse effects, analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use)
- Glucagon-Like Peptide-1 Receptor
- Humans
- Hypoglycemic Agents
(adverse effects, pharmacokinetics, pharmacology, therapeutic use)
- Liraglutide
- Pancreatic Neoplasms
(chemically induced)
- Pancreatitis
(chemically induced)
- Receptors, Glucagon
(agonists)
|